Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
Tocilizumab alone is superior to MTX alone.
Tocilizumab high dose yields and maintains better response than low dose.
Tocilizumab + MTX gives better response and remission rates than Tocilizumab alone. Only combination treatment significantly retarded joint damage as seen in XRays.
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
For inadequate responders to MTX alone, Tocilizumab + MTX gives superior response compared to Tocilizumab alone.